Enterprise Value

1.061B

Cash

742.3M

Avg Qtr Burn

N/A

Short % of Float

14.60%

Insider Ownership

0.31%

Institutional Own.

98.02%

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
MVC-COV1901 Details
COVID-19 Vaccine

Approved

Update

Heplisav-B Details
Infectious disease, Hepatitis B vaccine, Hepatitis B

Approved

Quarterly sales

Approved

Quarterly sales

Approved

Quarterly sales

Heplisav-B Details
Infectious disease, Hepatitis B vaccine, Hepatitis B

PDUFA

Approval decision

Phase 2

Data readout

Tdap-1018 (adjuvanted w/ CpG 1018) Details
Infectious disease, Tetanus, diphtheria, and pertussis

Phase 2

Initiation

Z-1018 (adjuvanted w/ CpG 1018) Details
Shingles, Viral infection, Infectious disease

Phase 1/2

Initiation

VLA2001 Details
Infectious disease, COVID-19

Failed

Discontinued